Major Depression Comorbid with Medical Conditions: Analysis of Quality of Life, Functioning, and Depressive Symptom Severity.
Authors: IsHak WW, Steiner AJ, Klimowicz A, Kauzor K, Dang J, Vanle B, Elzahaby C, Reid M, Sumner L, Danovitch I Abstract Background: The presence of Major Depressive Disorder (MDD) is often comorbid in patients with a variety of general medical conditions (GMCs) which could lead to less favorable outcomes. Objective: The goal of this analysis is to examine functional outcomes of QOL and functioning before and after antidepressant treatment among patients with MDD with and without GMCs. Methods: We performed a secondary analysis based on the STAR*D database. The analysis included two patient groups from the...
Source: Psychopharmacology Bulletin - February 1, 2018 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries.
Conclusions: In countries with high antidepressant utilization, higher doses of vortioxetine were required, and obverse was true in countries with lower antidepressant utilization. These data support the hypothesis that tolerance to serotonin reuptake inhibition drives poor antidepressant response. PMID: 29382958 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - February 1, 2018 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

The Use of Complementary Alternative Medicine in Children and Adolescents with Autism Spectrum Disorder.
Authors: DeFilippis M Abstract Complementary alternative medicine (CAM) is used to a greater degree in children and adolescents with autism spectrum disorder (ASD), when compared to children and adolescents without this diagnosis. There is limited evidence supporting the use of many of these treatments in ASD, despite their popularity. Current FDA approved medications for ASD target associated behavioral symptoms of the diagnosis, not the core symptoms of social communication deficits and restricted/repetitive behaviors. These medications are also associated with concerning adverse effects. Evidence-based therapies...
Source: Psychopharmacology Bulletin - February 1, 2018 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

The Black Book of Psychotropic Dosing and Monitoring.
Authors: Schatzberg AF, Charles D PMID: 29382960 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - February 1, 2018 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Erratum.
Authors: Abstract [This corrects the article on p. 29 in vol. 47, PMID: 28936006.][This corrects the article on p. 29 in vol. 47, PMID: 28936006.]. PMID: 29382961 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - February 1, 2018 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Dextromethorphan in Cough Syrup: The Poor Man's Psychosis.
We report a noteworthy case of severe dextromethorphan use disorder with dextromethorphan-induced psychotic disorder in a 40-year-old Caucasian female, whose symptoms remitted only following treatment with a combination of an antipsychotic and mood stabilizer. While some states have begun to limit the quantity of DXM sold or restrict sales to individuals over 18-years of age, there is currently no federal ban or restriction on DXM. Abuse of DXM, a readily available and typically inexpensive agent that is not detected on a standard urine drug screen, may be an under-recognized cause of substance-induced psychosis. It is imp...
Source: Psychopharmacology Bulletin - January 5, 2018 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Escitalopram Induced SIADH in an Elderly Female: A Case Study.
Authors: Vidyasagar S, Rao K, Verma M, Tripuraneni AD, Patil N, Bhattacharjee D Abstract Hyponatraemia is a well-established and potentially, a life-threatening adverse effect of selective serotonin receptor uptake inhibitors (SSRI). However, its occurrence secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) with escitalopram, has been reported extremely sporadically. The reporting of such rare, but life-threatening adverse effects of escitalopram assumes immense significance in light of the fact that SSRIs presently form the mainstay of treatment of depressive disorders. Here, we report a...
Source: Psychopharmacology Bulletin - January 5, 2018 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Persisting Psychosocial Impairments in Adults Being Treated with Medication for Attention Deficit/Hyperactivity Disorder.
Authors: Brown TE, Flood E, Sarocco P, Atkins N, Khachatryan A PMID: 28936004 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - September 24, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Unmet Medication Coverage Needs among Adults with Attention Deficit/Hyperactivity Disorder (ADHD).
Authors: Brown TE, Flood E, Sarocco P, Atkins N, Khachatryan A PMID: 28936005 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - September 24, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.
Authors: Dammerman R, Kim S, Adera M, Schwarz A PMID: 28936006 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - September 24, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.
Authors: Dammerman R, Kim S, Adera M, Schwarz A PMID: 28936007 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - September 24, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Physical Activity Diminishes Symptomatic Decline in Chronic Schizophrenia: A Systematic Review.
Authors: Tarpada SP, Morris MT Abstract Physical activity has been shown to positively influence a number of parameters in chronic schizophrenia, including cognition, social well being, and quality of life. Here, we present a systematic review of randomized controlled trials reporting on reduction of positive and negative symptoms using PANSS grading after the implementation of a physical activity protocol. Review of 64 articles yielded 6 relevant to our discussion. We found that physical activity significantly improved aggregate total PANSS score as well as positive symptoms PANSS score. While negative PANSS score...
Source: Psychopharmacology Bulletin - September 24, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Collaborative Care in Ambulatory Psychiatry: Content Analysis of Consultations to a Psychiatric Pharmacist.
CONCLUSIONS: This is a preliminary analysis that provides information about how psychiatry residents, attending physicians, and advanced practice nurse practitioners at our health system utilize a psychiatric pharmacist. This collaborative relationship may have implications for the future of psychiatric care delivery. PMID: 28936009 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - September 24, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Dextromethorphan in Cough Syrup: The Poor Man's Psychosis.
We report a noteworthy case of severe dextromethorphan use disorder with dextromethorphan-induced psychotic disorder in a 40-year-old Caucasian female, whose symptoms remitted only following treatment with a combination of an antipsychotic and mood stabilizer. While some states have begun to limit the quantity of DXM sold or restrict sales to individuals over 18-years of age, there is currently no federal ban or restriction on DXM. Abuse of DXM, a readily available and typically inexpensive agent that is not detected on a standard urine drug screen, may be an under-recognized cause of substance-induced psychosis. It is imp...
Source: Psychopharmacology Bulletin - September 24, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Escitalopram Induced SIADH in an Elderly Female: A Case Study.
Authors: Vidyasagar S, Rao K, Verma M, Tripuraneni AD, Patil N, Bhattacharjee D Abstract Hyponatraemia is a well-established and potentially, a life-threatening adverse effect of selective serotonin receptor uptake inhibitors (SSRI). However, its occurrence secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) with escitalopram, has been reported extremely sporadically. The reporting of such rare, but life-threatening adverse effects of escitalopram assumes immense significance in light of the fact that SSRIs presently form the mainstay of treatment of depressive disorders. Here, we report a...
Source: Psychopharmacology Bulletin - September 24, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder.
Authors: Brown B, Alphs L, Turkoz I, Yue Y PMID: 28839335 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - August 27, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Correlation of Caregiver Burden and Baseline Characteristics of Caregivers and Patients in Their Care with Recent-Onset Psychosis: The FIRST Study.
Authors: Mancevski B, Gogate J, Ashcroft K, Tardieu K, Kim E PMID: 28839336 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - August 27, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
CONCLUSION: AL allows for a range of dose/dose-interval combinations. The PK results from this study show that a dosing interval of every 8 weeks for the 1064 mg dose resulted in aripiprazole concentrations within the established therapeutic window for AL. There was no safety signal directing any particular concern to any of the three doses/dose intervals studied. All patients continued their primary antipsychotics without any apparent tolerability issue arising from the addition of the AL injections. The results of this study show that 1064 mg AL may be suitable for a 2-month dose interval. The three doses/dose intervals ...
Source: Psychopharmacology Bulletin - August 27, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
CONCLUSION: Long-term treatment with AL in outpatients with schizophrenia was associated with a modest lowering of serum prolactin for both genders and relatively modest changes in average weight, fasting glucose, and HbA1c values. There appeared to be little net change in lipid parameters. This presentation extends a recently published report on the short-term metabolic and endocrine effects of AL over a period of 12 weeks. The present study increased the follow-up period to more than a year and was careful to use the first exposure to AL as the baseline. Limitations include lack of a comparison group and difficulty disen...
Source: Psychopharmacology Bulletin - August 27, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
Authors: Luo R, Bozigian H, Jimenez R, Loewen G, O'Brien CF Abstract Valbenazine (VBZ) is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia. The safety, tolerability and pharmacokinetics of VBZ following single and repeat once-daily (QD) dosing were evaluated in 2 randomized, single-center, double-blind studies in healthy male subjects. In the first study, 2 cohorts of 8 subjects were administered single doses (SD) of placebo (PBO; N = 2/period) or VBZ (N = 6/period; 1, 2, 5, or 12.5 mg for Cohort 1 and 12.5, 25, 50, or 75 mg for Cohort 2) using a sequential esca...
Source: Psychopharmacology Bulletin - August 27, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
CONCLUSION: Sustained TD improvements were found in subjects with a mood disorder who received up to 48 weeks of VBZ, with TD reverting toward baseline severity when assessed 4 weeks after treatment withdrawal. Together with results from SCHZ subjects and the long-term safety profile (presented separately), these results indicate that long-term VBZ can be beneficial for managing TD regardless of psychiatric diagnosis. PMID: 28839340 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - August 27, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
CONCLUSION: Valbenazine appeared to be well tolerated in adults with TD who received up to 48 weeks of treatment. In addition to long-term efficacy results (presented separately), these results suggest that valbenazine may be appropriate for the long-term management of TD regardless of underlying psychiatric diagnosis (SCHZ disorder or mood disorder). PMID: 28839341 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - August 27, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
CONCLUSION: Sustained TD improvements were found in subjects with SCHZ who received up to 48 weeks of VBZ, with TD reverting toward baseline when assessed 4 weeks after treatment withdrawal. Together with results from mood disorder subjects and the long-term safety profile (presented separately), these results indicate that long-term VBZ can be beneficial for managing TD regardless of psychiatric diagnosis category. PMID: 28839342 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - August 27, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia - A Reference Guide.
Authors: PMID: 28839343 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - August 27, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders.
Authors: Kraal AZ, Ward KM, Ellingrod VL Abstract The adverse metabolic risks associated with second generation antipsychotics (SGAs) are well known, and likely contribute to the high rate of premature mortality due to cardiovascular disease in schizophrenia. Female schizophrenia patients appear to be diagnosed with metabolic diseases at higher rates than males, which may reflect disparate adverse responses to SGAs. However, the relationship between sex, metabolic risk, and drug use is less developed. We aimed to explore this relationship further by identifying rates of metabolic disease in community dwelling schiz...
Source: Psychopharmacology Bulletin - June 20, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

The Addition of Amphetamine to Potentially Sedating Medication Regimens: An Exploratory Investigation of the Impact upon Reaction Time and Sustained Attention.
CONCLUSION: Using PVT data, this exploratory study has provided information useful for generating the hypothesis that co-administration of an amphetamine with a sedating medication will result in arousal with a deficit of sustained attention related to the sedating medication's level of effect upon cholinergic activity. PMID: 28626269 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 20, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Impact of a Student Pharmacist Driven Medication Reconciliation and Antidepressant Treatment History Project at a Depression Clinic: A Pilot Study.
CONCLUSIONS: A student pharmacist pilot was feasible, identified many discrepancies in the medication record, and identified important medication treatment history in patients with depression in advance of the clinic visit. The project provides support for a specialized role for student pharmacists and demonstrates that interprofessional care can contribute to improved treatment of depression. PMID: 28626270 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 20, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
CONCLUSIONS: Overall, both 1-month and 3-month formulations of PDP are safe and effective in the treatment of schizophrenia and schizoaffective disorder. They may be most effective in patients with prior failed treatment of oral antipsychotics or other LAIAs, in patients with a history of medication noncompliance, or in patients with an individual preference for less frequent dosing. PMID: 28626271 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 20, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Aripiprazole-induced Asymptomatic Hypertension: A Case Report.
Authors: Seven H, Ayhan MG, Kürkcü A, Özbek S, Eren İ Abstract Aripiprazole is a second generation antipsychotic widely prescribed for the treatment of psychiatric diseases. It is generally known that antipsychotics have hypotensive effects. In this case report, however, we present the case of a medically healthy patient with schizophrenia who developed hypertension (HT) after the initiation of aripiprazole. The patient's blood pressure returned to normal after discontinuation of aripiprazole, suggesting that aripiprazole may have led to asymptomatic acute HT. PMID: 28626272 [PubMed - in process...
Source: Psychopharmacology Bulletin - June 20, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Combined Antipsychotics and Electroconvulsive Therapy in an Acutely Psychotic Patient with Treatment-resistant Schizophrenia.
Authors: Rayikanti R, Lentowicz I, Birur B, Li L Abstract Treatment of patients with Treatment-resistant Schizophrenia (TRS), who fail to respond to multiple antipsychotic trials, including clozapine (CLZ), is challenging. Several alternative strategies are reported in studies, one of which includes augmenting antipsychotics (AP) with Electroconvulsive therapy (ECT). We discuss a case of an acutely psychotic patient with TRS who responded effectively and sustained remission to this strategy which was ECT combined with two AP, CLZ and aripiprazole. Notable improvement in clinical and cognitive outcomes was seen with...
Source: Psychopharmacology Bulletin - June 20, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

A Review of Psychopharmacological Interventions Post-Disaster to Prevent Psychiatric Sequelae.
CONCLUSION: Hydrocortisone shows promise in preventing and reducing the psychiatric sequelae of PTSD following disasters. Further evaluation of hydrocortisone and other potentially beneficial psychopharmacological interventions are needed. PMID: 28559634 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Asenapine for the Control of Physical Aggression: A Prospective Naturalist Pilot Study.
Authors: Amon JS, Johnson SB, El-Mallakh RS Abstract It has been previously purported that higher relative affinity to the dopamine D4 receptor compared to D2 (i.e., D4/D2 affinity ratio> 1) may underlie unique antiaggression potency. Asenapine is a newer antipsychotic that also has D4/D2 affinity ratio> 1. It has demonstrated efficacy in reducing acute agitation in a placebo-controlled study. We performed a prospective naturalistic, pilot, proof of concept study on an inpatient psychiatric unit. Among patients with aggression at time of admission (≥ 12 on Refined Aggression Questionnaire [RAQ], or ≥ 2 ...
Source: Psychopharmacology Bulletin - June 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Treating an Adolescent with Long QT Syndrome for Bipolar Disorder: A Case Presentation.
CONCLUSIONS: LQTS is a serious health issue for children and adolescents diagnosed with BD. This condition should be kept in mind especially in cases where familial risk factors are present and precautions need to be maintained upon required assessments. These cases need to be closely monitored due to risk factors related to both BD and LQTS, in a multidisciplinary fashion, involving both psychiatry and cardiology divisions. PMID: 28559636 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.
Authors: Patel N, Landry KB, Fargason RE, Birur B Abstract Valproic acid (VPA) is an FDA-approved medication widely prescribed for seizures, migraines, and mixed or manic episodes in bipolar disorder. Hyperammonemia is a rare complication of VPA use, which can result in high morbidity and occasionally fatal encephalopathy. The scant literature on Valproate Induced Hyperammonemic Encephalopathy (VIHE) is characterized by acute onset of decreasing level of consciousness, drowsiness, lethargy which in rare instances can lead to seizures, stupor, coma, and persistent morbidity and cortical damage. Below we describe a c...
Source: Psychopharmacology Bulletin - June 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

A Case of Olanzapine-Induced Fever.
We describe a patient who developed isolated fever following olanzapine monotherapy, which subsided after discontinuation of olanzapine. Blockade of dopaminergic receptors and elevated cytokines concentration are possible mechanisms of fever development during treatment with olanzapine. This case calls for attention to olanzapine-induced fever in clinical practice. PMID: 28559638 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Opium Withdrawal Delirium: Two Case Reports.
Authors: Sharma RC, Kumar R, Sharma DD, Kanwar P Abstract Two patients with opium dependence developed delirium during abstinence. The delirium resolved completely within 48-58 hours of appropriate treatment. Caution needs to be exercised during opioid detoxification in timely detecting and treating potentially life-threatening condition like delirium. PMID: 28559639 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

A Review of Psychopharmacological Interventions Post-Disaster to Prevent Psychiatric Sequelae.
CONCLUSION: Hydrocortisone shows promise in preventing and reducing the psychiatric sequelae of PTSD following disasters. Further evaluation of hydrocortisone and other potentially beneficial psychopharmacological interventions are needed. PMID: 28138200 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - February 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Asenapine for the Control of Physical Aggression: A Prospective Naturalist Pilot Study.
Authors: Amon JS, Johnson SB, El-Mallakh RS Abstract It has been previously purported that higher relative affinity to the dopamine D4 receptor compared to D2 (i.e., D4/D2 affinity ratio> 1) may underlie unique antiaggression potency. Asenapine is a newer antipsychotic that also has D4/D2 affinity ratio> 1. It has demonstrated efficacy in reducing acute agitation in a placebo-controlled study. We performed a prospective naturalistic, pilot, proof of concept study on an inpatient psychiatric unit. Among patients with aggression at time of admission (≥ 12 on Refined Aggression Questionnaire [RAQ], or ≥ 2 ...
Source: Psychopharmacology Bulletin - February 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Treating an Adolescent with Long QT Syndrome for Bipolar Disorder: A Case Presentation.
CONCLUSIONS: LQTS is a serious health issue for children and adolescents diagnosed with BD. This condition should be kept in mind especially in cases where familial risk factors are present and precautions need to be maintained upon required assessments. These cases need to be closely monitored due to risk factors related to both BD and LQTS, in a multidisciplinary fashion, involving both psychiatry and cardiology divisions. PMID: 28138202 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - February 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.
Authors: Patel N, Landry KB, Fargason RE, Birur B Abstract Valproic acid (VPA) is an FDA-approved medication widely prescribed for seizures, migraines, and mixed or manic episodes in bipolar disorder. Hyperammonemia is a rare complication of VPA use, which can result in high morbidity and occasionally fatal encephalopathy. The scant literature on Valproate Induced Hyperammonemic Encephalopathy (VIHE) is characterized by acute onset of decreasing level of consciousness, drowsiness, lethargy which in rare instances can lead to seizures, stupor, coma, and persistent morbidity and cortical damage. Below we describe a c...
Source: Psychopharmacology Bulletin - February 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

A Case of Olanzapine-Induced Fever.
We describe a patient who developed isolated fever following olanzapine monotherapy, which subsided after discontinuation of olanzapine. Blockade of dopaminergic receptors and elevated cytokines concentration are possible mechanisms of fever development during treatment with olanzapine. This case calls for attention to olanzapine-induced fever in clinical practice. PMID: 28138204 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - February 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Opium Withdrawal Delirium: Two Case Reports.
Authors: Sharma RC, Kumar R, Sharma DD, Kanwar P Abstract Two patients with opium dependence developed delirium during abstinence. The delirium resolved completely within 48-58 hours of appropriate treatment. Caution needs to be exercised during opioid detoxification in timely detecting and treating potentially life-threatening condition like delirium. PMID: 28138205 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - February 2, 2017 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Extended Release Quetiapine Fumarate (Quetiapine XR) as Adjunct Therapy in Patients with Generalized Anxiety Disorder and a History of Inadequate Treatment Response: A Randomized, Double-Blind Study.
Authors: Khan A, Atkinson S, Mezhebovsky I, She F, Leathers T, Pathak S Abstract OBJECTIVE: To evaluate the efficacy and tolerability of adjunct extended release quetiapine fumarate (quetiapine XR) in patients with generalized anxiety disorder (GAD) and inadequate response to selective serotonin reuptake inhibitors/ serotonin norepinephrine reuptake inhibitors (SSRI/SNRIs). METHODS: 11-week (1-week single-blind placebo run-in; 8-week randomized treatment; 2-week post-treatment period), double-blind, placebo-controlled study. Patients were randomized to quetiapine XR or placebo adjunct to SSRI/SNRI. 50 mg initia...
Source: Psychopharmacology Bulletin - October 18, 2016 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Ramelteon for Insomnia Related to Attention-Deficit/Hyperactivity Disorder (ADHD).
CONCLUSIONS: Ramelteon is efficacious in maintaining an earlier sleep/wake cycle in adults with ADHD and CRSD but can have paradoxical fragmenting effects on sleep and exacerbate daytime sleepiness. In the presence of a circadian rhythm disorder, the usual dosing and timing parameters for ramelteon need to be carefully considered. PMID: 27738354 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - October 18, 2016 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia.
CONCLUSIONS: In this study, paliperidone ER 1.5 mg did not demonstrate efficacy in patients with acute schizophrenia. A markedly high placebo response was noted. Assay sensitivity with the 6 mg dose was not established. Paliperidone ER 1.5 mg was generally tolerable with a safety profile comparable to placebo. PMID: 27738355 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - October 18, 2016 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Zonisamide for Bipolar Depression: A Randomized, Double Blind, Placebo-Controlled, Adjunctive Trial.
CONCLUSIONS: In contrast to preliminary open label studies that suggested a role for zonisamide in bipolar depression, we could not confirm these results in a large double blind controlled study. PMID: 27738356 [PubMed - in process] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - October 18, 2016 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Monoarthritis Induced by Bupropion Hydrochloride.
Authors: Yuan W, Williams BN Abstract Bupropion hydrochloride is an inhibitor of dopamine and norepinephrine, which is commonly prescribed for major depression, smoking cessation, and bipolar depression. Here we report a highly unusual case of bupropion induced knee monoarthritis in a bipolar depression patient. With bupropion XL 150 mg for 2 weeks, her left knee began to swell; at the third week, this condition was worsening. The aggravation of the left knee effusion stopped after the discontinuation of bupropion XL. The effusion and swelling disappeared after 15 ml of synovial fluid was drawn out and the effusion...
Source: Psychopharmacology Bulletin - October 18, 2016 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Atomoxetine Induced Hypothermia: A Case Report.
Authors: Abali O, Yilmaz O Abstract Adverse drug reactions are common in drugs used during childhood and adolescence. Atomoxetine, a selective reuptake inhibitor, was introduced as a safe non-stimulant alternative treatment for attention deficit hyperactivity disorder. Described common side effects of atomoxetine include: headache, abdominal pain, decreased appetite, fatigue, nausea, vomiting and dizziness. In our case, we present an adolescent male who developed hypothermia under atomoxetine treatment. To our knowledge, this is the first report of a causal connection between atomoxetine intake and hypothermia. Bec...
Source: Psychopharmacology Bulletin - October 18, 2016 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

Rater Training for a Multi-Site, International Clinical Trial: What Mood Symptoms may be most Difficult to Rate?
Authors: Sajatovic M, Gaur R, Tatsuoka C, De Santi S, Lee N, Laredo J, Tripathi S Abstract AIMS: Given resource constraints in conducting clinical trials, it is critical that rater training focuses on scale items wherein standardization is most challenging. This analysis examined mood disorder symptom ratings submitted in an online rater training program conducted preparatory to the initiation of a multi-site, international mood disorder treatment trial. Ratings were entered online and analyzed for consistency and variability, and compared to established standards (Gold Consensus Ratings/ GCRs). METHODS: Raters...
Source: Psychopharmacology Bulletin - October 18, 2016 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research

The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder.
This report summarizes the safety and tolerability of vilazodone 40 mg/day during short- and long-term treatment of adult MDD. METHODS: Pooled data from two 8-week, double-blind studies of vilazodone (n = 436) vs placebo (n = 433) and data from one 52-week, open-label study (n = 616, vilazodone only) were analyzed. Patients aged 18-70 with DSM-IV-TR-defined MDD received vilazodone or placebo (8-week studies only) once daily, with food, titrated to 40 mg/day over 2 weeks. Safety and tolerability assessments included adverse events (AEs), laboratory tests, vital signs, electrocardiograms, and weight. RESULTS: The mos...
Source: Psychopharmacology Bulletin - October 18, 2016 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research